XTALPI (02228) saw its shares rise more than 7% after the announcement of its annual results. At the time of writing, the stock was up 6.94%, trading at HKD 9.71 with a turnover of HKD 257 million.

The company released its full-year performance figures, reporting annual revenue of RMB 803 million, a substantial increase of 201.25% year-on-year. During the period, it achieved a net profit of RMB 124 million, turning a loss into a profit compared to the previous year and marking its first annual profit. This milestone also makes XTALPI the first listed company on the Hong Kong stock exchange in the AI for Science sector to report an annual profit.

According to publicly available information, in 2025, XTALPI continued to deepen its focus on "AI for Science." While its antibody business experienced rapid growth, the company successfully expanded into multi-modal innovation platforms, including peptides, molecular glues, and nucleic acids. This has propelled its enabling services and the innovative pipelines of incubated companies into the validation phase. The diversification and success across its business lines have enabled XTALPI, which continues to advance its "AI for Science" platform, to formally enter a period of value realization characterized by "core innovation, commercial monetization, and performance validation."